- Home
- GTBP vs GLTO Comparison
GTBP vs GLTO Comparison
Compare GTBP & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- GLTO
- Stock Information
- Founded
- GTBP 1965
- GLTO 2011
- Country
- GTBP United States
- GLTO Denmark
- Employees
- GTBP N/A
- GLTO N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- GLTO Health Care
- Exchange
- GTBP Nasdaq
- GLTO Nasdaq
- Market Cap
- GTBP 5.5M
- GLTO 4.5M
- IPO Year
- GTBP N/A
- GLTO 2020
- Fundamental
- Price
- GTBP $1.77
- GLTO $3.40
- Analyst Decision
- GTBP Strong Buy
- GLTO Buy
- Analyst Count
- GTBP 1
- GLTO 1
- Target Price
- GTBP $11.00
- GLTO $10.00
- AVG Volume (30 Days)
- GTBP 74.2K
- GLTO 32.5K
- Earning Date
- GTBP 08-13-2025
- GLTO 08-11-2025
- Dividend Yield
- GTBP N/A
- GLTO N/A
- EPS Growth
- GTBP N/A
- GLTO N/A
- EPS
- GTBP N/A
- GLTO N/A
- Revenue
- GTBP N/A
- GLTO N/A
- Revenue This Year
- GTBP N/A
- GLTO N/A
- Revenue Next Year
- GTBP N/A
- GLTO N/A
- P/E Ratio
- GTBP N/A
- GLTO N/A
- Revenue Growth
- GTBP N/A
- GLTO N/A
- 52 Week Low
- GTBP $1.72
- GLTO $2.01
- 52 Week High
- GTBP $4.10
- GLTO $15.13
- Technical
- Relative Strength Index (RSI)
- GTBP 31.45
- GLTO 46.99
- Support Level
- GTBP $2.01
- GLTO $3.10
- Resistance Level
- GTBP $2.11
- GLTO $3.55
- Average True Range (ATR)
- GTBP 0.14
- GLTO 0.26
- MACD
- GTBP -0.01
- GLTO -0.05
- Stochastic Oscillator
- GTBP 8.77
- GLTO 30.93
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.